Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Lancet HIV. 2021 Dec;8(12):e766–e775. doi: 10.1016/S2352-3018(21)00265-4

Table 2:

Estimated total numbers and proportions of children and adolescents still alive with HIV viral load less than 1000 copies per mL by years on ART, stratified by IeDEA region (adjusted analysis)

Year 1
Year 2
Year 3
Estimated number with viral load <1000 copies per mL (plausible range) Total non-deaths Proportion with viral load <1000 copies per mL (plausible range) Estimated number with viral load <1000 copies per mL (plausible range) Total non-deaths Proportion with viral load <1000 copies per mL (plausible range) Estimated number with viral load <1000 copies per mL (plausible range) Total non-deaths Proportion with viral load <1000 copies per mL (plausible range)

Asia-Pacific 1192 (961–1259) 1426 84% (68–89) 1123 (887–1165) 1332 84% (67–87) 995 (778–1026) 1194 83% (65–86)
Caribbean, Central America, and South America 174 (125–201) 238 73% (53–84) 151 (110–180) 226 67% (49–80) 129 (91–150) 210 61% (43–71)
Central Africa 94 (55–109) 156 60% (35–70) 65 (36–74) 142 46% (25–52) NA NA NA
East Africa 3293 (2115–4115) 5085 65% (42–81) 2598 (1671–3279) 4312 60% (39–76) 1980 (1238–2454) 3478 57% (36–71)
Southern Africa 6459 (4311–8375) 10 194 63% (42–82) 6139 (3960–7740) 9901 62% (40–78) 5501 (3481–6855) 9256 59% (38–74)
West Africa 836 (586–1169) 1736 48% (34–67) 720 (492–999) 1640 44% (30–61) 572 (390–815) 1529 37% (26–53)
Overall 12 048 (8153–15 228) 18 835 64% (43–81) 10 796 (7156–13 437) 17 553 62% (41–77) 9177 (597–14 300) 15 667 59% (38–91)

ART consists of the combination of at least three antiretrovirals. Plausible ranges were generated by applying data for lower and upper bounds for the proportion of viral suppression using the literature reporting on viral outcomes among people with HIV in care (appendix pp 12). IeDEA=International epidemiology Databases to Evaluate AIDS. NA=not available.